Company Overview
Caprihans India Limited, a pharmaceutical packaging company, has disclosed its financial results for FY 2025-26 and announced its 80th Annual General Meeting scheduled for 26 September 2026.
Financial Performance
The company reported weak financial results with a standalone net loss of ₹48.17 crore on revenue of ₹710.25 crore, representing a reduction from the previous year's loss of ₹62.28 crore. On a consolidated basis, the net loss stood at ₹47.00 crore on revenue of ₹715.09 crore. The company maintains significant debt levels with total borrowings of ₹624.81 crore and a net debt-to-equity ratio of 154.48%. Key financial metrics show trade receivables of ₹103.94 crore and inventories of ₹114.66 crore as of March 31, 2026.
AGM and Corporate Governance
The 80th AGM will be held virtually on 26 September 2026, with key resolutions including:
- Adoption of audited financial statements for FY 2025-26
- Appointment of Mrs. Ankita J. Kariya as Director and Managing Director
- Ratification of cost auditor remuneration of ₹3.75 lakh
- Approval of 10% remuneration increases for key management personnel including MD Mrs. Ankita J. Kariya, Executive Director Mr. Somenath Mukherjee, President Mr. Shreyans Bhandari, and Vice-President Mrs. Ruchi S. Bhandari
- Approval of material related party transactions with promoter Bilcare Limited worth ₹100 crore (₹70 crore inter-corporate loans and ₹30 crore corporate guarantee)
Capital Structure and Related Party Transactions
The company's equity share capital increased to ₹15.91 crore from ₹14.62 crore due to conversion of 12,90,000 warrants into equity shares. Significant related party transactions include outstanding balances of ₹175.41 crore with holding company Bilcare Limited, comprising trade receivables, preference shares, and advance royalty payments.
Regulatory and Accounting Matters
The financial statements were prepared in accordance with Indian Accounting Standards (Ind AS) and SEBI regulations. The company identified and corrected a prior period error related to unaccounted lease contracts, resulting in restatement of FY25 figures with an increase in right-of-use assets of ₹6.89 crore and lease liabilities of ₹7.13 crore. Auditors issued an unmodified opinion with an emphasis of matter regarding arrangements with Bilcare Limited for repayment of public fixed deposit liability of ₹3.92 crore.
Operational Highlights
The company operates primarily in the pharmaceutical packaging segment with ₹456.83 crore revenue from India and ₹245.08 crore from international markets. Research and development expenditure increased to ₹2.73 crore, while contingent liabilities decreased to ₹8.26 crore from ₹13.51 crore in the previous year.
No dividend was recommended for FY 2025-26 due to continued business losses, and detailed e-voting instructions have been provided for shareholders to participate in the virtual AGM.